Andrew J. Peacock

10.9k total citations · 3 hit papers
96 papers, 4.3k citations indexed

About

Andrew J. Peacock is a scholar working on Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine and Genetics. According to data from OpenAlex, Andrew J. Peacock has authored 96 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Pulmonary and Respiratory Medicine, 35 papers in Cardiology and Cardiovascular Medicine and 12 papers in Genetics. Recurrent topics in Andrew J. Peacock's work include Pulmonary Hypertension Research and Treatments (64 papers), Cardiovascular Function and Risk Factors (22 papers) and High Altitude and Hypoxia (11 papers). Andrew J. Peacock is often cited by papers focused on Pulmonary Hypertension Research and Treatments (64 papers), Cardiovascular Function and Risk Factors (22 papers) and High Altitude and Hypoxia (11 papers). Andrew J. Peacock collaborates with scholars based in United Kingdom, United States and Germany. Andrew J. Peacock's co-authors include Martin Johnson, Marius M. Hoeper, Hossein Ardeschir Ghofrani, David Welsh, Nazzareno Galiè, Anton Vonk Noordegraaf, Ekkehard Grünig, John Τ. Reeves, Gérald Simonneau and Adaani Frost and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Andrew J. Peacock

88 papers receiving 4.2k citations

Hit Papers

3 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension

2015 750 citations Nazzareno Galiè, Joan Albert Barberà et al. New England Journal of Medicine profile →
Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension

2013 411 citations Marius M. Hoeper, Robyn J. Barst et al. Circulation profile →
Changing Demographics, Epidemiology, and Survival of Incident Pulmonary Arterial Hypertension: Results from the Pulmonary Hypertension Registry of the United Kingdom and Ireland

2012 392 citations Yi Ling, Martin Johnson et al. American Journal of Respiratory and Critical Care Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrew J. Peacock United Kingdom	32	3.3k	2.2k	554	455	424	96	4.3k
René P. Michel Canada	23	2.1k 0.6×	947 0.4×	236 0.4×	448 1.0×	796 1.9×	100	3.6k
Natascha Sommer Germany	28	1.6k 0.5×	980 0.5×	138 0.2×	730 1.6×	420 1.0×	113	3.0k
D Heath United Kingdom	32	1.6k 0.5×	822 0.4×	174 0.3×	637 1.4×	337 0.8×	147	3.5k
Paul McLoughlin Ireland	32	1.9k 0.6×	384 0.2×	132 0.2×	701 1.5×	576 1.4×	92	3.2k
Gail Deutsch United States	36	2.1k 0.6×	372 0.2×	214 0.4×	1.7k 3.7×	354 0.8×	111	5.3k
Abraham Rothman United States	28	1.2k 0.4×	841 0.4×	164 0.3×	464 1.0×	173 0.4×	116	2.9k
Donald Heath United Kingdom	30	1.8k 0.5×	778 0.4×	193 0.3×	561 1.2×	230 0.5×	86	3.2k
Keiko Uchida Japan	35	754 0.2×	484 0.2×	250 0.5×	1.8k 3.9×	360 0.8×	233	4.9k
James S. Hagood United States	43	2.8k 0.9×	190 0.1×	357 0.6×	1.9k 4.2×	380 0.9×	101	5.7k
Joseph A. Lasky United States	39	2.7k 0.8×	148 0.1×	342 0.6×	1.4k 3.1×	592 1.4×	109	4.7k

Countries citing papers authored by Andrew J. Peacock

Since Specialization

Citations

This map shows the geographic impact of Andrew J. Peacock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew J. Peacock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew J. Peacock more than expected).

Fields of papers citing papers by Andrew J. Peacock

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew J. Peacock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew J. Peacock. The network helps show where Andrew J. Peacock may publish in the future.

Co-authorship network of co-authors of Andrew J. Peacock

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew J. Peacock. A scholar is included among the top collaborators of Andrew J. Peacock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew J. Peacock. Andrew J. Peacock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kiely, David G., Richard N. Channick, Dayana Flores, et al.. (2024). Comparison of cardiac magnetic resonance imaging, functional and haemodynamic variables in pulmonary arterial hypertension: insights from REPAIR. ERJ Open Research. 10(1). 547–2023. 1 indexed citations

Wilson, K., Kornelija Suveizdytė, John T. Liles, et al.. (2020). Apoptosis signal‐regulating kinase 1 inhibition in in vivo and in vitro models of pulmonary hypertension. Pulmonary Circulation. 10(2). 1–16. 5 indexed citations

Jayasekera, Geeshath, K. Wilson, Rosemary Woodward, et al.. (2019). Understanding longitudinal biventricular structural and functional changes in a pulmonary hypertension Sugen–hypoxia rat model by cardiac magnetic resonance imaging. Pulmonary Circulation. 10(1). 1–11. 10 indexed citations

Kerridge, Simon, Colin Church, Andrew J. Peacock, et al.. (2018). Social deprivation and prognosis in Scottish patients with pulmonary arterial hypertension. European Respiratory Journal. 51(2). 1700444–1700444. 10 indexed citations

Galiè, Nazzareno, Joan Albert Barberà, Adaani Frost, et al.. (2015). Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. New England Journal of Medicine. 373(9). 834–844. 750 indexed citations breakdown →

Brewis, Melanie, Colin Church, Martin Johnson, & Andrew J. Peacock. (2015). Severe pulmonary hypertension in lung disease: phenotypes and response to treatment. European Respiratory Journal. 46(5). 1378–1389. 48 indexed citations

Hoeper, Marius M., Robyn J. Barst, Robert C. Bourge, et al.. (2013). Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension. Circulation. 127(10). 1128–1138. 411 indexed citations breakdown →

Welsh, David & Andrew J. Peacock. (2013). Cellular Responses to Hypoxia in the Pulmonary Circulation. High Altitude Medicine & Biology. 14(2). 111–116. 38 indexed citations

Peacock, Andrew J., Kevin G. Blyth, Carmine Dario Vizza, et al.. (2013). Changes in Right Ventricular Function Measured by Cardiac Magnetic Resonance Imaging in Patients Receiving Pulmonary Arterial Hypertension–Targeted Therapy. Circulation Cardiovascular Imaging. 7(1). 107–114. 111 indexed citations

10.

Carlin, C, et al.. (2012). Low-Dose Fluvastatin Reverses the Hypoxic Pulmonary Adventitial Fibroblast Phenotype in Experimental Pulmonary Hypertension. American Journal of Respiratory Cell and Molecular Biology. 47(2). 140–148. 17 indexed citations

11.

Ling, Yi, Martin Johnson, David G. Kiely, et al.. (2012). Changing Demographics, Epidemiology, and Survival of Incident Pulmonary Arterial Hypertension: Results from the Pulmonary Hypertension Registry of the United Kingdom and Ireland. American Journal of Respiratory and Critical Care Medicine. 186(8). 790–796. 392 indexed citations breakdown →

12.

Hoeper, Marius M., Robyn J. Barst, Nazzareno Galiè, et al.. (2011). Imatinib in pulmonary arterial hypertension, a randomized, efficacy study (IMPRES). European Respiratory Journal. 38(Suppl 55). 413–413. 11 indexed citations

13.

Ghofrani, Hossein Ardeschir, Nicholas W. Morrell, Marius M. Hoeper, et al.. (2010). Imatinib in Pulmonary Arterial Hypertension Patients with Inadequate Response to Established Therapy. American Journal of Respiratory and Critical Care Medicine. 182(9). 1171–1177. 291 indexed citations

14.

Toshner, Mark, A. A. Roger Thompson, John B. Irving, et al.. (2008). NT-proBNP Does Not Rise on Acute Ascent to High Altitude. High Altitude Medicine & Biology. 9(4). 307–310. 16 indexed citations

15.

Eleftheriou, Kyriacos I., Emma Hawe, Ian Watt, et al.. (2004). Performance at altitude and angiotensin I-converting enzyme genotype. European Journal of Applied Physiology. 93(5-6). 630–633. 42 indexed citations

16.

Welsh, David, Margaret M. Harnett, Margaret R. MacLean, & Andrew J. Peacock. (2004). Proliferation and Signaling in Fibroblasts. American Journal of Respiratory and Critical Care Medicine. 170(3). 252–259. 86 indexed citations

17.

Peacock, Andrew J.. (1998). Oxygen at high altitude. BMJ. 317(7165). 1063–1066. 204 indexed citations

18.

Peacock, Andrew J., Pamela Scott, Robin Plevin, R. M. Wadsworth, & David Welsh. (1998). Hypoxia Enhances Proliferation and Generation of IP3 in Pulmonary Artery Fibroblasts But Not in Those From the Mesenteric Circulation. CHEST Journal. 114(1). 24S–24S. 12 indexed citations

19.

Scott, Pamela, Christopher Belham, Edwin R. Chilvers, et al.. (1996). A regulatory role for cAMP in phosphatidylinositol 3-kinase/p70 ribosomal S6 kinase-mediated DNA synthesis in platelet-derived-growth-factor-stimulated bovine airway smooth-muscle cells. Biochemical Journal. 318(3). 965–971. 102 indexed citations

20.

Peacock, Andrew J., K E Dawes, Anthony Shock, et al.. (1992). Endothelin-1 and Endothelin-3 Induce Chemotaxis and Replication of Pulmonary Artery Fibroblasts. American Journal of Respiratory Cell and Molecular Biology. 7(5). 492–499. 117 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact